Koers Arch Biopartners Inc. Other OTC
Aandelen
ACHFF
CA03938C1041
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 2 mln. 1,47 mln. 1,35 mln. | Omzet 2025 * | 2 mln. 1,47 mln. 1,35 mln. | Marktkapitalisatie | 106 mln. 77,81 mln. 71,64 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | 53 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 53 x |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 80,44% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Daniel Muruve
FOU | Founder | - | 04-03-83 |
Richard Muruve
FOU | Founder | - | 04-03-83 |
Andrew Bishop
DFI | Director of Finance/CFO | 58 | 01-04-10 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Richard Rossman
BRD | Director/Board Member | - | 07-05-10 |
Richard Muruve
FOU | Founder | - | 04-03-83 |
Claude Allary
BRD | Director/Board Member | 69 | 01-04-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+33,63% | 50,85 mld. | |
-0,09% | 42,82 mld. | |
+49,62% | 42,03 mld. | |
-4,96% | 29,55 mld. | |
+11,18% | 26,11 mld. | |
-21,95% | 19,13 mld. | |
+8,61% | 13,05 mld. | |
+28,31% | 12,16 mld. | |
+24,73% | 12,08 mld. |